Recent Milestones: September 2023: NHS England and Scotland publish positive national evaluations endorsing the use of EndoSign® across the United Kingdom October 2023: European Society of Gastrointestinal Endoscopy recommends Cyted’s technology, capsule sponge testing. for Barrett’s esophagus in updated guidance for Barrett’s esophagus screening and case finding. December 2023: Cyted received a £1M grant from Innovate UK to launch a precision medicine initiative using EndoSign® for non-endoscopic testing of Eosinophilic Esophagitis (EoE), aiming to improve diagnosis, treatment decisions, and patient outcomes. This is Cyted’s R&D push into a new indication with significant unmet need. January 2024: Start of the BEST4 trial, which will recruit 120,000 patients to assess the potential of EndoSign® as a national screening program to reach even more patients with the goal to prevent esophageal cancer. January 2024: CLIA laboratory setup completed and FDA clearance received to launch EndoSign® in the US.
 

Upcoming Milestones: First reimbursed Heartburn Health Check with EndoSign® in the US later in 2024 with rate setting expected around $2000 per test in June. R&D developments including dysplasia biomarker project and a European/American collaboration for EndoSign in Barrett’s and dysplasia testing. Cyted to begin Series B fundraise.
 

Products: EndoSign®, a minimally-invasive platform with multiple biomarker tests to detect early signs of cancer and protect esophageal health.

Investors: Morningside & BGF

Full Company address & contact details: 22 Station Road, Cambridge, CB1 2JD, UK.